title: Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.
abstract: This report compares the pharmacokinetics and the bioavailabilities of the antifactor Xa and of the antifactor IIa activities generated by intravenous (IV) and subcutaneous (SC) injections of increasing doses of unfractionated heparin (UH) and of a low molecular weight heparin (CY 216). Rabbits were injected with 500, 1,000, 2,500, and 5,000 antifactor Xa u/kg of both heparins and their biological activities were followed at various time intervals. After IV injection the clearance of the antifactor Xa activities was independent of the dose and the clearance of UH was significantly higher than that of CY 216; after SC injection the bioavailability estimated from the antifactor Xa effect was consistently over 100% for CY 216 while that of UH increased from 27% at the lowest dose to 93% at the highest dose. The pharmacokinetic parameters estimated by the antifactor IIa activity of UH were superimposable to those calculated with the antifactor Xa activity. For CY 216 no direct comparison between the two activities was made since the dose injected expressed in antifactor IIa units was 3.4 times lower. UH and CY 216 were therefore injected intravenously to other animals at equivalent and increasing doses expressed in antifactor IIa units (50-5,000 u/kg). The pharmacokinetic parameters calculated from the curves of the antifactor IIa activities were basically identical except at the two lower doses (50 and 100 u/kg) for which UH was cleared faster than CY 216.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Laboratoire d'Hémostase, Centre de Transfusion, Toulouse, France.
authors.forename: L
authors.initials: L
authors.lastname: Briant
authors.forename: C
authors.initials: C
authors.lastname: Caranobe
authors.forename: S
authors.initials: S
authors.lastname: Saivin
authors.forename: P
authors.initials: P
authors.lastname: Sié
authors.forename: B
authors.initials: B
authors.lastname: Bayrou
authors.forename: G
authors.initials: G
authors.lastname: Houin
authors.forename: B
authors.initials: B
authors.lastname: Boneu
mesh_terms: D000818:Animals; D001682:Biological Availability; D001780:Blood Coagulation Tests; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000493:pharmacokinetics*; D006495:Heparin, Low-Molecular-Weight / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D011516:Prothrombin / Q000037:antagonists & inhibitors*; D011817:Rabbits
chemical_list: D065427:Factor Xa Inhibitors; D006495:Heparin, Low-Molecular-Weight; D011516:Prothrombin; C025337:Factor IIa; D006493:Heparin